In patients with cirrhosis of the liver, acute kidney injury (AKI) is classified into 3 stages. Recent studies indicate that there are 2 subgroups of stage 1 disease, associated with different outcomes and serum levels of creatinine (SCr): stage 1A (SCr <1.5 mg/dL) and stage 1B (SCr ‡1.5 mg/dL). We performed a prospective study to validate, in a large series of patients with cirrhosis, the association between this new description and patient outcomes, and assess the relationship between AKI stage and the presence of acute-on-chronic liver failure.
time. Moreover, AKI is classified in 3 different stages (1, 2, and 3) depending on the intensity of changes in SCr. This staging classification correlates with prognosis in patients with cirrhosis, [7] [8] [9] [10] because stages 2 and 3 have worse prognosis compared with stage 1. However, this classification does not take into account important features of kidney function characteristic of cirrhosis. Of note, because of the labile kidney circulation, it is the clinical experience that patients with cirrhosis frequently present small variations of SCr levels that are readily reversible. These variations occur spontaneously or secondary to specific circumstances, such as diuretic therapy or episodes of moderate hypovolemia. However, the impairment of kidney function in cirrhosis occurs frequently in association with failure of other organs, a condition known as acute-on-chronic liver failure (ACLF), which may impact negatively in the prognosis of patients with AKI. 11, 12 Two recent studies from independent groups proposed dividing patients in stage 1 AKI into 2 different categories according to a cutoff level of SCr. 7, 8 This proposal was based on findings of different prognosis between patients with stage 1 with SCr <1.5 mg/dL (133 mmol/L) and those with stage 1 and SCr !1.5 mg/dL. On this basis, we designed the current study to prospectively validate in a large series of patients with cirrhosis a modification of the staging classification of AKI based on SCr levels at diagnosis of AKI stage 1. Outcomes studied were survival and progression of AKI. In addition, we assessed AKI resolution and the relationship between AKI stages and the concomitant presence of ACLF.
Methods

Study Population
This prospective study includes 547 patients admitted for acute decompensation of cirrhosis to 2 liver units of tertiary hospitals, the University Hospital of Padova 
Study Design
Demographic and clinical data were recorded at admission. Liver and kidney tests were assessed at admission and at regular intervals throughout hospitalization. Patients were followed up until death, liver transplantation, or end of 90-day follow-up.
Definitions
Acute kidney injury. AKI was defined as an increase in SCr !0.3 mg/dL with respect to baseline according to International Club of Ascites criteria. 3 The presence of AKI was assessed at hospital admission. For this purpose, baseline SCr was defined as the most recent stable SCr available in the previous 3 months before admission. 3 In patients without a value of SCr within the previous 3 months, the last stable value of SCr available between 3 months and 1 year was used as baseline. 7, 9 Hospital-acquired AKI was defined when AKI was absent at admission and developed during hospitalization. For this purpose, SCr measured during hospitalization was used as baseline. AKI was defined independently of whether patients had normal or abnormal baseline SCr concentration.
Acute kidney injury stages. AKI stages were defined as follows: stage 1, increase in SCr !0.3 mg/dL (26.5 mmol/L) or an increase in !1.5-fold to 2-fold from baseline; stage 2, increase in SCr between 2-fold and 3-fold from baseline; and stage 3, increase of SCr >3-fold from baseline or SCr !4.0 mg/dL with an acute increase !0.3 mg/dL or initiation of renal-replacement therapy. 6 For the purposes of this study, patients in stage 1 were subclassified into 2 categories according to the value of SCr at diagnosis of AKI: stage 1A, if SCr was <1.5 mg/dL or stage 1B if SCr was !1.5 mg/dL. Therefore, patients with AKI were classified into 4 different stages: 1A, 1B, 2, and 3. Staging of AKI was assessed at first fulfilment of AKI criteria (stage at diagnosis) and during the hospitalization following the evolution of AKI (maximum stage).
Acute-on-chronic liver failure. ACLF was defined following the diagnostic criteria of the Canonic study and classified in ACLF I, II, or III.
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Other definitions. Definitions of resolution and progression of AKI, type of AKI, and chronic kidney disease are provided in the Supplementary Material.
Management of Acute Kidney Injury and Complications of Cirrhosis
See the Supplementary Material.
Statistical Analysis
Methods used to perform the statistical analysis are reported in the Supplementary Material.
Results
Characteristics of the Study Population
The characteristics of patients at the time of admission to hospital are shown in Supplementary Table 1 Patients with AKI 1B had similar baseline characteristics compared with those with AKI 1A except for a more frequent history of diabetes and chronic kidney disease before admission and ascites at admission and higher SCr and model for end-stage liver disease score at diagnosis of AKI. Figure 1 shows the individual values of SCr at baseline (ie, last value before the episode of AKI) and diagnosis of AKI, and the peak value during hospitalization in patients with stage 1A and 1B. There were obvious differences between the 2 groups at all time points. Median values were 0.86, 1.3, and 1.4 mg/dL, respectively, in patients with stage 1A, and 1.3, 1.9, and 2.3 mg/dL, respectively, in patients with stage 1B.
To evaluate the relationship between baseline kidney function and development of stage 1A versus 1B, we compared mean differences between SCr at diagnosis of AKI and baseline SCr; and peak SCr during hospitalization and baseline SCr. The mean difference between SCr at diagnosis of AKI and baseline SCr was significantly higher for AKI 1B compared with that of AKI 1A patients. The same hold true for the mean difference between SCr peak and baseline SCr (Table 1 ). These findings indicate that the difference between stage 1B and 1A was not merely the consequence of a higher baseline SCr in 1B versus 1A, but also of a remarkably greater impairment in kidney function in the former compared with the latter.
Further comparison between patients with stage 1A and those with stage 1B revealed major differences with respect to outcome of kidney function. As shown in Table 2 , the rate of progression of AKI, maximum AKI stage, peak SCr, and need for renal-replacement therapy were significantly higher in patients with AKI 1B than in those with AKI 1A. In multivariate analysis, AKI 1B compared with AKI 1A was an independent predictive factor of AKI progression (Supplementary Table 3 ). By contrast, rate of AKI resolution during hospitalization was significantly greater in patients with stage 1A compared with those with stage 1B. In fact, 90% of patients with stage 1A showed resolution of AKI in comparison with only half of patients with stage 1B (Table 2) . Moreover, stage 1B was an independent predictive factor of lack of AKI resolution.
We next analyzed the relationship between AKI stages and type of AKI. Interestingly, there were marked differences in types of AKI when patients were classified according to AKI stages ( Figure 2) . Overall, the frequency of prerenal azotemia was higher in patients with stages 1A and 1B than in patients with stages 2 and 3, whereas the frequencies of hepatorenal syndrome (HRS) and acute tubular necrosis were higher in patients with stages 2 and 3 compared with those with low AKI stages. Remarkably, frequencies of HRS and acute tubular necrosis were significantly greater in stage 1B compared with those with stage 1A (34% and 14% vs 12% and 3%, respectively; P < .005 for both).
We next investigated whether categorization of patients in stages 1A and 1B was associated with prognosis. Supplementary Figure 1 shows that 90-day transplant-free survival of patients with stage 1A was markedly higher than that of patients with stage 1B (84% compared with only 58%, respectively; P < .001). A similar difference in survival between patients with stages 1A and 1B was also observed when only patients with bacterial infections were considered (85% compared with 55%; P < .001). Survival of patients with stage 1A was slightly lower than that of patients without AKI, yet the difference did not reach statistical significance (84% vs 89%; P ¼ .238). Ninety-day probability of survival of patients with stage 2 and 3 were 48% and 43%, respectively.
In the whole series, the univariate analysis of survival showed several clinical and laboratory variables associated with prognosis (Supplementary Table 4 ). In multivariate analysis, factors independently associated with 90-day transplant-free survival were age, model for end-stage liver disease score, serum sodium, leukocyte count, and modified AKI stage (Table 3 , model 1). Interestingly, AKI stage 1A was not an independent predictor of mortality in multivariate analysis. By contrast, presence of AKI stage 1B was associated with an increased mortality risk (hazard ratio, 2.54 with respect to patients without AKI), further confirming the difference between AKI stage 1A and 1B with respect to patient outcome. The best cutoff point of SCr for determining 3-month prognosis in patients with AKI stage 1 was of 1.54 mg/dL, as assessed by the Youden index. This value is very close to the level of 1.5 mg/dL used in the current study.
We also examined whether the different outcome of patients with stages 1A and 1B could be associated to a different prevalence of ACLF between the 2 categories. Table 4 shows that there was a direct relationship between AKI stages and prevalence of ACLF. Of note, the frequency of ACLF in patients with stage 1B was much greater than that of patients with stage 1A (76% vs 22%, respectively; P < .001). Remarkably, in patients with stage 1B, presence of ACLF was not only related to higher frequency of kidney failure, but also to a greater frequency of liver, brain, coagulation, respiratory, and circulatory failures (Table 4) . Finally, when ACLF was included in the multivariate analysis, ACLF grade but not AKI stage was an independent predictor of mortality (Table 3 , model 2), which emphasizes the critical role of ACLF in determining prognosis in those patients.
Discussion
We report the results of a prospective investigation aimed at improving AKI staging in patients with cirrhosis. The current study validates the results from previous studies about differences between AKI stage 1A and 1B with respect to progression of AKI and survival. 7, 8 However, the most important and novel findings of the current investigation are that AKI stage 1A and 1B are also different with respect to (1) AKI resolution, (2) type of AKI, and (3) prevalence of ACLF. Resolution of AKI during hospitalization was markedly different between the 2 categories. The absolute difference in AKI resolution between patients with stage 1A and those with stage 1B was of 38% (90% vs 52%, respectively; P < .001). Moreover, another important difference was that in patients with stage 1A, HRS and acute tubular necrosis were very uncommon types of AKI (12% and 3%, respectively), whereas they accounted for 48% of cases in patients with stage 1B. By contrast, the most common type of AKI in stage 1A was prerenal AKI, which accounted for almost half of the cases, compared with only 27% in stage 1B. Finally, another relevant difference between stages 1A and 1B was the prevalence of ACLF. ACLF is a syndrome that occurs in patients with cirrhosis, characterized by presence of organ failures and impaired short-term survival.
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Frequency of ACLF was markedly lower in patients with stage 1A compared with stage 1B, 22% vs 76%, respectively. It could be argued that considering that kidney failure is a component of ACLF, the greater frequency of ACLF in AKI 1B patients could be exclusively accounted for by a more marked kidney impairment compared with AKI 1A. However, patients with AKI 1B, not only had greater frequency of kidney failure (as defined in ACLF criteria), but also greater frequency of all other organ failures compared with those of patients with AKI 1A (Table 4) . Therefore, our findings indicate that in most cases AKI 1B occurs in the setting of an ACLF syndrome, whereas AKI 1A in general occurs as an isolated impairment of kidney function, usually of prerenal origin.
The results of the current study also confirm previous observations from our groups indicating that AKI stage 1A and 1B patients have markedly different outcomes of kidney function and prognosis. 7, 8 In fact, progression rate of AKI was 2 times higher in patients with AKI 1B compared with that of patients with AKI 1A, and stage 1B but not 1A was an independent predictive factor of AKI progression in multivariate analysis. Progression of AKI is a major issue because it is associated with deleterious consequences, particularly prolonged hospitalizations, need for renal-replacement therapy, increased resource utilization, high number of associated complications, and poor prognosis. 2, 4 Moreover, another difference between categories was survival. Patients with stage 1A had a 90-day probability of transplant-free survival of 84%, a figure markedly higher than that of patients with AKI 1B, which was of 58%. Similar figures were found if only patients with AKI associated with bacterial infections were considered. Furthermore, the 90-day survival of patients with AKI 1A (84%) was close to that of patients without AKI, which was of 89%, a difference that was not statistically significant. Remarkably, in multivariate analyses of survival, stage 1A did not increase significantly the risk of death compared with that of patients without AKI.
The results of the current study and those from previous studies 7, 8 differ from those reported in a post hoc analysis performed in patients with cirrhosis and bacterial infections. 14, 15 In this latter analysis, patients with bacterial infections and a peak SCr <1.5 mg/dL (n ¼ 31) (stage 1A of the current study), had a 81% 30-day survival, not significantly different (P ¼ .09) from that of patients with a peak SCr !1.5 mg/dL (n ¼ 135) (stage 1B of the current study), which was of 63%. Assessment of the 204 patients with bacterial infections and AKI from the current investigation showed a marked statistically significant difference in 30-day survival between patients with AKI 1A and those with AKI 1B (86% vs 56%, respectively; P ¼ .002).
As proposed in recent consensus recommendations, patients with AKI stage 1 should be managed by removing risk factors (eg, diuretics, nonsteroidal anti-inflammatory drugs) or treating triggering factors, but neither plasma volume expansion nor specific treatment of AKI are recommended.
3 Findings of the current investigation provide the basis for performing a prospective interventional study using the categorization of stage 1 in 1A and 1B to guide patient management. Interventions in patients with stage 1A may consist only of removing/treating precipitating factors, whereas stage 1B patients may require a more aggressive intervention based on volume expansion followed by other therapies if there is no response to volume expansion (ie, terlipressin and albumin for patients with HRS). Management of ACLF should also be considered given the high prevalence of ACLF in patients with AKI 1B.
In conclusion, on the basis of findings of this prospective study we therefore propose a new classification for staging of patients with cirrhosis and AKI that divides stage 1 into 2 different categories, A and B, depending on SCr levels at diagnosis of AKI. This classification is clinically sound because it takes into account the marked differences in types of AKI, outcome of kidney function, associated ACLF, and survival. Furthermore, this study emphasizes the need for assessing the presence of ACLF in patients with cirrhosis and AKI.
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Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at http://dx.doi.org/10.1016/j.cgh.2016.09.156. by means of log-rank test. Patients transplanted during follow-up were considered censored at the time of transplantation. Organ allocation is performed according to model of end-stage liver disease score in both centers, with median model of end-stage liver disease score at transplantation of 26. A stepwise Cox proportional hazards model, with backward elimination (variable entry/ drop criteria, P < .05/P > .1), was performed to identify independent predictors of 3-month survival. The hazard ratios and their 95% confidence intervals were calculated. A stepwise logistic regression analysis with backward elimination was used to identify independent predictors of in-hospital mortality, AKI stage progression, and AKI resolution. The odds ratios and their 95% confidence interval were calculated. Youden index was used to assess the best cutoff of SCr for prediction of mortality. Nonnormally distributed continuous variables were logtransformed to be included in multivariate models. When scores of liver disease were included in multivariate analyses their components were excluded to avoid colinearity. All tests were 2-tailed and P values < .05 were considered significant. The statistical analysis was performed using SPSS statistical package, version 20.0 (IBM Corp, Armonk, NY).
